Sun Pharma's Ilumetri Included in China's National Reimbursement Drug List Category B

14 Dec 2023 , 12:00 PM

Sun Pharmaceutical announces the inclusion of Ilumetri in category B of China’s national reimbursement drug list. Ilumetri, designed for adults with moderate-to-severe plaque psoriasis, is set to be officially implemented on January 1, 2024.

Sun Pharma had out-licensed Tildrakizumab (Ilumetri) to a subsidiary of China Medical System Holdings Ltd in June 2019. Ilumetri received marketing approval in China in May 2023. The inclusion in the national reimbursement drug list is expected to enhance accessibility and affordability, benefiting a broader patient population.

For feedback and suggestions, write to us at [e-mail]